OBJECTIVE: This review delves into phycocyanin applications in diabetes and its complications and ascertains the mechanisms involved.
METHODS: Scopus, PubMed, Cochrane Library, Web of Science, and ProQuest databases were systematically reviewed (up to April 30, 2023), in which only animal and cellular studies were found.
RESULTS: According to animal studies, the administration of phycocyanin affected biochemical parameters (primary outcome) related to diabetes. These results showed an increase in fasting insulin serum and a decrease in fasting blood glucose, glycosylated serum protein, and glycosylated hemoglobin. In cellular studies, though, phycocyanin prevented methylglyoxal and human islet amyloid polypeptide-induced dysfunction in β-cells and induced apoptosis through different molecular pathways (secondary outcome), including activation of Nrf2, PI3K/Akt, and suppression of JNK and p38. Also, phycocyanin exerted its antidiabetic effect by affecting the pathways regulating hepatic glucose metabolism.
CONCLUSIONS: Thus, based on the available information and literature, targeting these pathways by phycocyanin may unleash an array of benefits, including positive outcomes of the antidiabetic effects of phycocyanin as a nutraceutical.
UNASSIGNED: This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) at the National Institute of Health. The registration number is CRD42022307522.
目的:本文对藻蓝蛋白在糖尿病及其并发症中的应用进行了综述,并对其作用机制进行了探讨。
方法:Scopus,PubMed,科克伦图书馆,WebofScience,和ProQuest数据库进行了系统审查(截至2023年4月30日),其中只有动物和细胞研究被发现。
结果:根据动物研究,藻蓝蛋白的给药会影响与糖尿病相关的生化指标(主要结局).这些结果表明,空腹胰岛素血清增加,空腹血糖下降,糖化血清蛋白,和糖化血红蛋白.在细胞研究中,虽然,藻蓝蛋白预防甲基乙二醛和人胰岛淀粉样多肽诱导的β细胞功能障碍,并通过不同的分子途径诱导细胞凋亡(次要结果),包括激活Nrf2,PI3K/Akt,以及抑制JNK和p38。此外,藻蓝蛋白通过影响调节肝脏葡萄糖代谢的途径发挥其抗糖尿病作用。
结论:因此,根据现有的信息和文献,通过藻蓝蛋白靶向这些途径可能会释放一系列益处,包括藻蓝蛋白作为营养药物的抗糖尿病作用的积极结果。
■该系统评价已在美国国立卫生研究院的国际系统评价前瞻性注册(PROSPERO)中注册。注册号为CRD42022307522。